172 results on '"Horsfall, Leigh"'
Search Results
2. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
3. Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD)
4. Longitudinal Change in Simple Scores Identifies Fibrosis Status in People With Nonalcoholic Fatty Liver Disease
5. Serum CCL2 is associated with visceral adiposity but not fibrosis in patients with Non-alcoholic Fatty Liver Disease (NAFLD).
6. Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis
7. Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care
8. Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C
9. Triage of referrals to outpatient hepatology services: An ineffective tool to prioritise patients?
10. Serum CC-Chemokine Ligand 2 Is Associated with Visceral Adiposity but Not Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
11. Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)
12. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease
13. Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety
14. Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests
15. ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity
16. Towards collaborative management of non-alcoholic fatty liver disease: a ‘real-world’ pathway for fibrosis risk assessment in primary care
17. Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis
18. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease
19. Nonalcoholic fatty liver disease: interface between primary care and hepatology clinics
20. Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)
21. Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)
22. The Patient’s Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age
23. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM
24. Assessment of health‐related quality of life and health utilities in Australian patients with cirrhosis
25. BMI But Not Stage or Etiology of Nonalcoholic Liver Disease Affects the Diagnostic Utility of Carbohydrate-Deficient Transferrin
26. Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C
27. Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.
28. CDT as a biomarker of alcohol excess in patients with chronic liver disease: BMI affects diagnostic sensitivity
29. ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies
30. Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis
31. Development of a supportive needs assessment tool for cirrhosis (SNAC)
32. Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics
33. Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention
34. Assessment of health‐related quality of life and health utilities in Australian patients with cirrhosis.
35. Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control
36. A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care
37. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes
38. An exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia
39. Identifying areas of need relative to liver disease: geographic clustering within a health service district
40. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis
41. Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management
42. Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial
43. Multimorbidity and polypharmacy in diabetic patients with NAFLD
44. Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia
45. Identifying areas of need relative to liver disease: geographic clustering within a health service district
46. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease
47. Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease
48. Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers
49. Prevalence of medication discrepancies in patients with cirrhosis: a pilot study
50. Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.